Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659461 | 0.80 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL7265318 | 0.79 | CYP19A1 (0.38) | CYP19A1 | |
| SCHEMBL6250570 | 0.76 | — | — | |
| SCHEMBL11617 | 0.74 | FDPS (0.33) | — | |
| SCHEMBL29092717 | 0.74 | MEN1 (0.43) | — | |
| Ammonia Solution, Strong SCHEMBL27898568 | 0.73 | FDPS (0.32) | — | |
| SCHEMBL3303673 | 0.71 | — | — | |
| SCHEMBL15032983 | 0.70 | DGAT1 (0.32) | — | |
| SCHEMBL28201638 | 0.69 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL4606038 | 0.68 | DGAT1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357615-B2 | Compositions for the treatment of brain tumors | KEMBI THERAPEUTICS PTY LTD (AU) | 2025-07-15 | — | — | US | disclosed |
| US-20220370415-A1 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | KEMBI THERAPEUTICS PTY LTD (AU) | 2022-11-24 | — | — | US | disclosed |
| WO-2019182743-A1 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | INNOCRIN PHARMACEUTICALS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-108707177-A | 20- triazol radical -20- hydroxyls-pregnant steroid derivatives and preparation method thereof and medical usage | 中国药科大学 | 2018-10-26 | — | — | CN | disclosed |
| EP-2638021-B1 | 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer | INNOCRIN PHARMACEUTICALS INC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1070066-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-a]PYRIDAZINE | MERCK SHARP & DOHME LTD. (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000027849-A2 | THERAPEUTIC POLYMORPHS OF A GABA-A ALPHA-5 INVERSE AGONIST AND PAMOATE FORMULATIONS OF THE SAME | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027382-A2 | COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND COX-2 INHIBITOR, NSAID, ESTROGEN OR VITAMIN E | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0986562-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999043677-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PYRIDAZINE | MERCK SHARP & DOHME LIMITED (GB) | 1999-09-02 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP19A1 898/4885 |
| US-20220370415-A1 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | NR3C2, NR3C1, CRH | CYP19A1 1262/4885 |
| US-12357615-B2 | Compositions for the treatment of brain tumors | NR3C2, NR3C1, CRH | CYP19A1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.